We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Salsalate Shown To Reduce Diabetes Risk

By HospiMedica staff writers
Posted on 12 Feb 2008
Diabetes researchers have found that the anti-inflammatory drug salsalate reduced glycemia and seemed to improve inflammatory cardiovascular risk indexes in overweight individuals at risk for development of type 2 diabetes.

Investigators at the Joslin Diabetes Center (Boston, MA, USA) selected salsalate for their proof-of-concept clinical study, since it blocks formation of the peripheral prostaglandins that cause pain and inflammation without inhibiting platelet aggregation. More...
In the study, 20 obese young adults received either salsalate or a placebo in a double-masked protocol.

Results published in the February 2008 issue of the journal Diabetes Care revealed that those who took 4 g of salsalate per day for one month reduced fasting glucose levels by 13% and levels of C-reactive protein, a marker for inflammation, by 34%. Glycemic response after an oral glucose challenge dropped by 20%, and glycated albumin levels fell by 17%.

"This is exciting because salsalate has a good safety profile after many years of use, is inexpensive to make, and appears to have the potential to lower blood glucose,” said senior author Dr. Allison B. Goldfine, assistant professor of cellular and molecular physiology at the Joslin Diabetes Center. "Our study was the first to look at the metabolic changes that occur when you give salsalate to obese people who have not yet developed diabetes, and we are really encouraged by what we found. Although the drug was around, no one ever thought of using it in diabetes/metabolic syndrome.”


Related Links:
Joslin Diabetes Center

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.